Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.81)
# 711
Out of 5,049 analysts
229
Total ratings
51.08%
Success rate
8.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Overweight | $163 → $168 | $141.96 | +18.34% | 30 | Oct 20, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $167 → $180 | $138.38 | +30.08% | 11 | Oct 20, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $113.74 | +13.42% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $42.85 | +79.70% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $41.90 | +88.54% | 5 | Sep 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $19 → $18 | $6.92 | +160.12% | 4 | Sep 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $67.95 | +4.49% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $7.81 | +258.51% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $10.65 | +97.18% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $2.38 | -15.97% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $7.26 | +79.06% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $8.86 | +1,118.96% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $33.47 | +64.33% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.37 | +7.29% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $84.69 | +0.37% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $23.91 | +12.92% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $7.42 | -32.61% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $60.03 | +11.61% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.02 | +398.58% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $3.98 | +0.50% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.61 | +148.45% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $6.56 | +113.41% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.18 | +19.62% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.95 | +1.69% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.84 | +660.87% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.72 | +481.40% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $38.06 | -42.20% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $14.85 | +900.00% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.39 | +4,216.55% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.58 | +31.00% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $11.98 | +5,309.02% | 6 | May 8, 2020 |
Neurocrine Biosciences
Oct 20, 2025
Maintains: Overweight
Price Target: $163 → $168
Current: $141.96
Upside: +18.34%
Jazz Pharmaceuticals
Oct 20, 2025
Maintains: Overweight
Price Target: $167 → $180
Current: $138.38
Upside: +30.08%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $113.74
Upside: +13.42%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $42.85
Upside: +79.70%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $41.90
Upside: +88.54%
enGene Holdings
Sep 12, 2025
Maintains: Overweight
Price Target: $19 → $18
Current: $6.92
Upside: +160.12%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $67.95
Upside: +4.49%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $7.81
Upside: +258.51%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.65
Upside: +97.18%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $2.38
Upside: -15.97%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $7.26
Upside: +79.06%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $8.86
Upside: +1,118.96%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $33.47
Upside: +64.33%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.37
Upside: +7.29%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $84.69
Upside: +0.37%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $23.91
Upside: +12.92%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $7.42
Upside: -32.61%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $60.03
Upside: +11.61%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.02
Upside: +398.58%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $3.98
Upside: +0.50%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.61
Upside: +148.45%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $6.56
Upside: +113.41%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.18
Upside: +19.62%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.95
Upside: +1.69%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.84
Upside: +660.87%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.72
Upside: +481.40%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $38.06
Upside: -42.20%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $14.85
Upside: +900.00%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.39
Upside: +4,216.55%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.58
Upside: +31.00%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $11.98
Upside: +5,309.02%